Form D · Biotechnology
Dualitas Therapeutics, Inc.
South San Francisco, CA · CIK 0002091994
Offering snapshot reported Nov 18, 2025 · SEC filing
- Reported sold
- $32.6M Offering amount: $66.6M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 7, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 18, 2025 | Initial | $32,599,997 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564321
Includes conversion of $15,600,000 in simple agreements for future equity.
Source: Form D, filed Nov 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Forbes Huang | Executive |
| Thomas Hudson | Director |
| Greg Lazar | Executive |
| Alicia Levey | Director |
| Mark Mc Dade | Director |
| Richard Murray | Director, Executive |
| Michael Ross | Director |
| Nikola Trbovic | Director |
| Neil Weir | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
681 Gateway Boulevard, Suite 411
South San Francisco, CA, 94080
South San Francisco, CA, 94080